NASDAQ : NEUP
Neuphoria Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.05 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 16.50M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 16.50M |
| Enterprise Value | -3.33M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 5.41M |
| Shares Outstanding | 5.41M |
| Shares Change (YoY) | +170.86% |
| Shares Change (QoQ) | -0.07% |
| Owned by Insiders (%) | 0.73% |
| Owned by Institutions (%) | 41.74% |
| Float | 5.37M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.06 |
| Forward PS | n/a |
| PB Ratio | 0.67 |
| P/TBV Ratio | 0.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 27.85 |
| Quick Ratio | 27.33 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -61.70% |
| Return on Assets (ROA) | -19.65% |
| Return on Invested Capital (ROIC) | -25.72% |
| Return on Capital Employed (ROCE) | -32.23% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $1.17M |
| Profits Per Employee | -$13.45M |
| Employee Count | 1 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -139,173 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | -33.41% |
| 50-Day Moving Average | 3.58 |
| 200-Day Moving Average | 4.16 |
| Relative Strength Index (RSI) | 25.47 |
| Average Volume (20 Days) | 29,488 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6,429 |
| Short Previous Month | 20,022 |
| Short % of Shares Out | 0.12% |
| Short % of Float | 0.12% |
| Short Ratio (days to cover) | 0.43 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.17M |
| Gross Profit | 1.17M |
| Operating Income | -9.01M |
| Pretax Income | -13.59M |
| Net Income | -13.45M |
| EBITDA | -8.35M |
| EBIT | -9.01M |
| Loss Per Share | -$3.06 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 19.87M |
| Total Debt | 34,345 |
| Net Cash | 19.83M |
| Net Cash Per Share | $3.66 |
| Equity (Book Value) | 24.60M |
| Book Value Per Share | 4.55 |
| Working Capital | 20.31M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -12.35M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 662,955 |
| Net Borrowing | n/a |
| Free Cash Flow | -12.35M |
| FCF Per Share | -$2.28 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -767.32% |
| Pretax Margin | -1,157.51% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -170.86% |
| Shareholder Yield | n/a |
| Earnings Yield | -100.33% |
| FCF Yield | -74.85% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -6.24 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |